Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) Shares Outstanding (Weighted Average) (2016 - 2025)

Cytosorbents' Shares Outstanding (Weighted Average) history spans 15 years, with the latest figure at $62.2 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $62.2 million for Q4 2025, up 14.32% from a year ago — trailing twelve months through Dec 2025 was $62.2 million (up 14.32% YoY), and the annual figure for FY2025 was $62.2 million, up 14.32%.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $62.2 million at Cytosorbents, roughly flat from $62.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $62.6 million in Q2 2025 to a low of $2.7 million in Q4 2023.
  • The 5-year median for Shares Outstanding (Weighted Average) is $43.6 million (2022), against an average of $44.5 million.
  • The sharpest move saw Shares Outstanding (Weighted Average) tumbled 93.79% in 2023, then skyrocketed 1911.21% in 2024.
  • Year by year, Shares Outstanding (Weighted Average) stood at $43.4 million in 2021, then grew by 0.49% to $43.6 million in 2022, then tumbled by 93.79% to $2.7 million in 2023, then skyrocketed by 1911.21% to $54.4 million in 2024, then rose by 14.32% to $62.2 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $62.2 million, $62.0 million, and $62.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.